

# CITATION REPORT

List of articles citing

## Immunobiology and pathogenesis of viral hepatitis

DOI: 10.1146/annurev.pathol.1.110304.100230  
Annual Review of Pathology: Mechanisms of Disease,  
2006, 1, 23-61.

**Source:** <https://exaly.com/paper-pdf/39749886/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
607	Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein. <b>2007</b> , 20, 56-65		67
606	The role of cells refractory to productive infection in acute hepatitis B viral dynamics. <b>2007</b> , 104, 5050-5		81
605	Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus. <b>2007</b> , 81, 483-91		36
604	B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. <b>2007</b> , 178, 6634-41		108
603	Integration of technologies for hepatic tissue engineering. <b>2007</b> , 103, 309-29		60
602	Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. <b>2007</b> , 81, 100-7		106
601	HBV pathogenesis in animal models: recent advances on the role of platelets. <b>2007</b> , 46, 719-26		75
600	The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. <b>2007</b> , 47, 632-41		68
599	Response to interferon-alpha treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B. <b>2007</b> , 47, 751-9		15
598	Specific immune response to HBsAg is enhanced by beta-glucan oligosaccharide containing an alpha-(1->3)-linked bond and biased towards M2/Th2. <b>2007</b> , 7, 725-33		35
597	Modeling the mechanisms of acute hepatitis B virus infection. <b>2007</b> , 247, 23-35		127
596	Clinical immune characterization of hepatitis B virus infection and implications for immune intervention: Progress and challenges. <b>2007</b> , 37 Suppl 3, S339-46		16
595	Tumor-associated protein SPIK/TATI suppresses serine protease dependent cell apoptosis. <b>2008</b> , 13, 483-94		20
594	Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. <b>2008</b> , 47, 1437-45		183
593	Immunopathology of hepatitis B virus infection. <b>2008</b> , 27, 427-46		13
592	Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. <b>2008</b> , 27 Suppl 2, S31-42		131
591	Suppression of p38 mitogen-activated protein kinase inhibits hepatitis B virus replication in human hepatoma cell: the antiviral role of nitric oxide. <b>2008</b> , 15, 490-497		15

590	Suppression of p38 mitogen-activated protein kinase inhibits hepatitis B virus replication in human hepatoma cell: the antiviral role of nitric oxide. <b>2008</b> , 15, 490-7	18
589	Dynamics of a delay differential equation model of hepatitis B virus infection. <b>2008</b> , 2, 140-53	105
588	Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. <b>2008</b> , 49, 396-406	82
587	Retrovirus-specificity of regulatory T cells is neither present nor required in preventing retrovirus-induced bone marrow immune pathology. <b>2008</b> , 29, 782-94	50
586	Aberrant lymphocyte activation precedes delayed virus-specific T-cell response after both primary infection and secondary exposure to hepadnavirus in the woodchuck model of hepatitis B virus infection. <b>2008</b> , 82, 6992-7008	15
585	Mouse models in liver cancer research: a review of current literature. <b>2008</b> , 14, 6915-23	63
584	HBV X protein: elucidating a role in oncogenesis. <b>2008</b> , 3, 455-470	
583	Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. <b>2008</b> , 14, 7149-59	97
582	Macrophages in hepatitis B and hepatitis C virus infections. <b>2009</b> , 83, 2796-802	59
581	Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the Woodchuck model of hepatitis B virus infection. <b>2009</b> , 83, 3861-76	22
580	Hepatitis Viruses. <b>2009</b> , 354-375	
579	Involvement of creatine kinase B in hepatitis C virus genome replication through interaction with the viral NS4A protein. <b>2009</b> , 83, 5137-47	37
578	Decreased parietal cortex activity during mental rotation in children with congenital hypothyroidism. <b>2009</b> , 89, 56-65	14
577	Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. <b>2009</b> , 20, 930-42	75
576	Correlation of circulating TLR2/4 expression with CD3+/4+/8+ T cells and Treg cells in HBV-related liver cirrhosis. <b>2009</b> , 22, 301-8	17
575	New insights into HBV replication: new opportunities for improved therapies. <b>2009</b> , 4, 55-70	19
574	Immune defence, parasite evasion strategies and their relevance for 'macroscopic phenomena' such as virulence. <b>2009</b> , 364, 85-98	133
573	Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. <b>2009</b> , 15, 1443-61	130

572	Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I. <b>2009</b> , 384, 12-5	7
571	Translational insensitivity to potent activation of PKR by HCV IRES RNA. <b>2009</b> , 83, 228-37	49
570	Reply:. <b>2009</b> , 49, 1780-1781	1
569	Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models. <b>2009</b> , 50, 1380-91	20
568	The amazing universe of hepatic microstructure. <b>2009</b> , 50, 333-44	24
567	Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway. <b>2009</b> , 50, 1370-9	29
566	Frequencies and characterization of HBV-specific cytotoxic T lymphocytes in self-limited and chronic hepatitis B viral infection in China. <b>2009</b> , 29, 567-74	6
565	Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. <b>2009</b> , 16, 156-67	66
564	Tumour virology--history, status and future challenges. <b>2009</b> , 117, 382-99	8
563	Chronic viral hepatitis is a significant contributor to the immunosenescent phenotype of parenteral drug addiction. <b>2009</b> , 14, 214-26	8
562	Repression of hepatitis B viral gene expression by transcription factor nuclear factor-kappaB. <b>2009</b> , 11, 645-60	24
561	Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways. <b>2009</b> , 11, 1624-37	46
560	Redefining chronic viral infection. <b>2009</b> , 138, 30-50	727
559	Why actively promote vaccination in patients with cirrhosis?. <b>2009</b> , 46, 206-9	16
558	On the role of platelets in the pathogenesis of viral hepatitis. <b>2009</b> , 51, 599-600	11
557	Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. <b>2009</b> , 51, 458-67	116
556	Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through downregulating CD59. <b>2009</b> , 47, 283-9	15
555	Treatment of HBV/HCV coinfection: releasing the enemy within. <b>2009</b> , 136, 393-6	22

554	Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. <b>2009</b> , 137, 1289-300	279
553	Cellular and molecular biology of HCV infection and hepatitis. <b>2009</b> , 117, 49-65	98
552	A case of severe acute hepatitis C and delayed antibody production due to rituximab therapy. <b>2010</b> , 3, 254-8	1
551	Hepatitis B and the Immune System. <b>2010</b> , 9, 205-213	
550	HBV Drug Resistance Development, Testing, and Prevention. <b>2010</b> , 9, 223-230	1
549	Effect of regulatory T cells and adherent cells on the expansion of HBcAg-specific CD8+ T cells in patients with chronic hepatitis B virus infection. <b>2010</b> , 264, 42-6	8
548	Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. <b>2010</b> , 401, 197-206	61
547	Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. <b>2010</b> , 51, 1144-57	130
546	Bioluminescence imaging allows measuring CD8 T cell function in the liver. <b>2010</b> , 51, 1430-7	35
545	Combinatorial effects of interleukin 10 and interleukin 4 determine the progression of hepatic inflammation following murine enteric parasitic infection. <b>2010</b> , 51, 2162-71	14
544	Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks. <b>2010</b> , 52, 1242-50	15
543	How chronic viral infections impact on antigen-specific T-cell responses. <b>2010</b> , 40, 654-63	76
542	Role of the HBx oncoprotein in carbonic anhydrase 9 induction. <b>2010</b> , 82, 32-40	15
541	Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. <b>2010</b> , 3, 48	47
540	Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. <b>2010</b> , 90, 1690-703	88
539	A look behind closed doors: interaction of persistent viruses with dendritic cells. <b>2010</b> , 8, 350-60	51
538	. <b>2010</b> ,	
537	Hypothesis: Targeted deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes. <b>2010</b> , 2010, 39-47	4

536	Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation. <b>2010</b> , 184, 4185-95	36
535	Suppression of innate immune pathology by regulatory T cells during Influenza A virus infection of immunodeficient mice. <b>2010</b> , 84, 12564-75	55
534	Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. <b>2010</b> , 84, 9332-40	100
533	CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice. <b>2010</b> , 185, 7654-62	38
532	Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. <b>2010</b> , 84, 5277-93	109
531	Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment?. <b>2010</b> , 23, 633-8	51
530	Clinical relevance of genetic heterogeneity in HCV. <b>2010</b> , 5, 33-49	5
529	Intrahepatic IL-10 maintains NKG2A+Ly49- liver NK cells in a functionally hyporesponsive state. <b>2010</b> , 184, 2693-701	90
528	Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. <b>2010</b> , 9, 2924-33	84
527	Innate antiviral immune responses to hepatitis B virus. <b>2010</b> , 2, 1394-410	49
526	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. <b>2010</b> , 2, 2696-739	31
525	Hepatocyte-specific deletion of DDB1 induces liver regeneration and tumorigenesis. <b>2010</b> , 107, 22237-42	34
524	Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis. <b>2010</b> , 84, 907-17	26
523	Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. <b>2010</b> , 2, 32ra35	134
522	Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. <b>2010</b> , 138, 305-14	78
521	Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. <b>2010</b> , 138, 1134-42	62
520	HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. <b>2010</b> , 329, 174-80	238
519	Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. <b>2010</b> , 16, 277-86	56

518	APOBEC1 and APOBEC3 cytidine deaminases as restriction factors for hepadnaviral genomes in non-humans in vivo. <b>2010</b> , 400, 323-34	33
517	Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. <b>2010</b> , 110, 228-33	39
516	Pathogenesis of hepatitis B virus infection. <b>2010</b> , 58, 258-66	277
515	Hepatitis B virus (HBV)-derived DRB1*0101-restricted CD4 T-cell epitopes help in the development of HBV-specific CD8+ T cells in vivo. <b>2010</b> , 28, 3818-26	7
514	Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice. <b>2010</b> , 28, 5323-31	4
513	Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. <b>2010</b> , 176, 2259-68	55
512	Hepatitis B immunology for clinicians. <b>2010</b> , 14, 409-24	13
511	Stability analysis and simulation of an anti-HBV therapy mathematical model with time-delay immune response. <b>2011</b> ,	
510	Dynamics of Hepatitis B Virus Infection: What Causes Viral Clearance?. <b>2011</b> , 18, 87-105	16
509	Biomedical differences between human and nonhuman hominids: potential roles for uniquely human aspects of sialic acid biology. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2011</b> , 6, 365-93 <sup>34</sup>	87
508	Hepatitis B virus limits response of human hepatocytes to interferon- $\beta$ in chimeric mice. <b>2011</b> , 140, 2074-83, 2083.e1-2	119
507	Regulation of hepatocyte fate by interferon- $\gamma$ <b>2011</b> , 22, 35-43	73
506	Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. <b>2011</b> , 305, 123-43	112
505	Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. <b>2011</b> , 55, 278-88	87
504	Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. <b>2011</b> , 55, 963-71	104
503	Bioengineering in organ transplantation: targeting the liver. <b>2011</b> , 43, 2137-8	47
502	Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. <b>2011</b> , 17, 3322-9	104
501	Receptor-mediated T cell absorption of antigen presenting cell-derived molecules. <b>2011</b> , 16, 411-21	20

500	Immunopathogenesis of HIV/hepatitis C virus coinfection. <b>2011</b> , 6, 1115-1128	1
499	Hepatitis B. <b>2011</b> , 367-392	3
498	An experimental mouse model for hepatitis C virus. <b>2011</b> , 60, 93-100	7
497	Lactate dehydrogenase production in hepatocytes is increased at an early stage of acute liver failure. <b>2011</b> , 2, 195-199	27
496	Sustained seroconversion of chronic hepatitis B infection after stem cell transplantation. <b>2011</b> , 15, E92-5	3
495	Adaptive immune responses during acute uncomplicated and fulminant hepatitis E. <b>2011</b> , 26, 306-11	33
494	Peripheral blood monocyte subsets predict antiviral response in chronic hepatitis C. <b>2011</b> , 34, 960-71	19
493	A rapid chemokine response of macrophage inflammatory protein (MIP)-1 $\beta$ and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C. <b>2011</b> , 17, 204-9	14
492	Serine 204 phosphorylation and O-GlcNAc interplay of IGFBP-6 as therapeutic indicator to regulate IGF-II functions in viral mediated hepatocellular carcinoma. <b>2011</b> , 8, 208	5
491	Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. <b>2011</b> , 91, 23-31	51
490	Dendritic cells in hepatitis C infection: can they (help) win the battle?. <b>2011</b> , 46, 432-47	23
489	Hepatitis B virus infection, its sequelae, and prevention by vaccination. <b>2011</b> , 23, 237-43	40
488	Vitamins in the treatment of chronic viral hepatitis. <b>2011</b> , 105, 982-9	9
487	Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. <b>2011</b> , 85, 1048-57	91
486	HIV-1 coinfection and morphine coexposure severely dysregulate hepatitis C virus-induced hepatic proinflammatory cytokine release and free radical production: increased pathogenesis coincides with uncoordinated host defenses. <b>2011</b> , 85, 11601-14	29
485	Plant viral epitope display systems for vaccine development. <b>2014</b> , 375, 47-59	9
484	Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. <b>2011</b> , 7, e1002061	88
483	Hepatitis B virus X protein activates CD59 involving DNA binding and let-7i in protection of hepatoma and hepatic cells from complement attack. <b>2011</b> , 32, 1190-7	35



482	Modulation of apoptotic signaling by the hepatitis B virus X protein. <b>2012</b> , 4, 2945-72	58
481	Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. <b>2012</b> , 33, 466-72	53
480	Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. <b>2012</b> , 19, 1027-37	17
479	Immunology of Liver. <b>2012</b> , 233-275	
478	Effects of telbivudine treatment on the circulating CD4+ T-cell subpopulations in chronic hepatitis B patients. <b>2012</b> , 2012, 789859	20
477	Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. <b>2012</b> , 109, E2165-72	225
476	The proapoptotic Bcl-2 family member Bim plays a central role during the development of virus-induced hepatitis. <b>2012</b> , 188, 916-22	9
475	A functional insertion/deletion polymorphism in the proximal promoter of CD3G is associated with susceptibility for hepatocellular carcinoma in Chinese population. <b>2012</b> , 31, 1480-5	4
474	Cytokines and HCV-related disorders. <b>2012</b> , 2012, 468107	64
473	Acute and chronic viral hepatitis. <b>2012</b> , 361-401	5
472	Interleukin-1R signaling is essential for induction of proapoptotic CD8 T cells, viral clearance, and pathology during lymphocytic choriomeningitis virus infection in mice. <b>2012</b> , 86, 8713-9	16
471	Lentivirally overexpressed T-bet regulates T-helper cell lineage commitment in chronic hepatitis B patients. <b>2012</b> , 6, 361-6	3
470	Chronic hepatitis B infection and pregnancy. <b>2012</b> , 67, 37-44	23
469	NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. <b>2012</b> , 92, 967-77	114
468	NKT cells--an early warning system for HBV infection. <b>2012</b> , 18, 1014-6	8
467	Molecular characterization of woodchuck interleukin-10 receptor and enhanced function of specific T cells from chronically infected woodchucks following its blockade. <b>2012</b> , 35, 563-73	3
466	The immunopathogenetic role of autoantibodies in canine autoimmune hepatitis: lessons to learn from human autoimmune hepatitis. <b>2012</b> , 3, 87-93	1
465	Analysis of a HBV infection model with ALT. <b>2012</b> ,	

464	Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis. <b>2012</b> , 30, 5595-602	39
463	IL-2-engineered nano-APC effectively activates viral antigen-mediated T cell responses from chronic hepatitis B virus-infected patients. <b>2012</b> , 188, 1534-43	6
462	Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. <b>2012</b> , 57, 522-8	57
461	Identification of HLA-A*0201-restricted CD8+ T-cell epitope $\text{C}\alpha\text{I}$ from hepatitis B virus core protein. <b>2012</b> , 13, 141-7	11
460	Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. <b>2012</b> , 56, 1706-18	30
459	Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. <b>2012</b> , 10, 158	11
458	Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model. <b>2012</b> , 9, 280	11
457	Role of monokine induced by interferon- $\beta$ in liver injury induced by hepatitis B virus in mice. <b>2012</b> , 19, 509-18	6
456	Microporous membrane-based liver tissue engineering for the reconstruction of three-dimensional functional liver tissues in vitro. <b>2012</b> , 2, 290-5	5
455	Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. <b>2012</b> , 143, 1586-1596.e8	92
454	The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. <b>2012</b> , 96, 405-13	51
453	Molecular characterization of the type I IFN receptor in two woodchuck species and detection of its expression in liver samples from woodchucks infected with woodchuck hepatitis virus (WHV). <b>2012</b> , 60, 179-85	11
452	Clinical Implications of the Innate and Adaptive Immune Response to HBV and HCV. <b>2012</b> , 11, 243-249	
451	Downregulation of the AU-rich RNA-binding protein ZFP36 in chronic HBV patients: implications for anti-inflammatory therapy. <b>2012</b> , 7, e33356	5
450	Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors. <b>2012</b> , 7, e36984	24
449	Nonprimate hepaciviruses in domestic horses, United kingdom. <b>2012</b> , 18, 1976-82	86
448	A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies. <b>2012</b> , 44, 55-9	7
447	Hepatitis C virus infection enhances TNF $\beta$ -induced cell death via suppression of NF- $\kappa$ B. <b>2012</b> , 56, 831-40	60

446	Platelets harness the immune response to drive liver cancer. <b>2012</b> , 109, 12840-1	20
445	Cutting SRC-1 down to size in endometriosis. <b>2012</b> , 18, 1016-8	13
444	Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. <b>2012</b> , 18, 1060-8	170
443	Potential role of soluble B7-H3 in liver immunopathogenesis during chronic HBV infection. <b>2012</b> , 19, 23-31	9
442	Medical virology of hepatitis B: how it began and where we are now. <b>2013</b> , 10, 239	184
441	Chronic hepatitis B: what should be the goal for new therapies?. <b>2013</b> , 98, 27-34	95
440	The HepaRG cell line: a valuable in vitro tool for hepatitis virus infection studies. <b>2013</b> , 7, 394-9	1
439	Relevance of interleukin-10RB to chronic hepatitis B virus infection and biological activities of interferon- $\beta$ and interleukin-22. <b>2013</b> , 7, 111-8	5
438	HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. <b>2013</b> , 78, 439-46	22
437	Association of TNF- $\beta$ with left ventricular diastolic dysfunction in patients with hepatitis C virus infection. <b>2013</b> , 168, 2903-4	4
436	Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. <b>2013</b> , 59, 1135-8	62
435	Persistent LCMV infection is controlled by blockade of type I interferon signaling. <b>2013</b> , 340, 207-11	527
434	Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C. <b>2013</b> , 20, 556-65	16
433	Control of human viral infections by natural killer cells. <b>2013</b> , 31, 163-94	303
432	Experimental models and therapeutic approaches for HBV. <b>2013</b> , 35, 7-21	33
431	Lactosylated poly(ethylene oxide)poly(propylene oxide) block copolymers for potential active targeting: synthesis and physicochemical and self-aggregation characterization. <b>2013</b> , 15, 1	7
430	Reduced type I interferon production by dendritic cells and weakened antiviral immunity in patients with Wiskott-Aldrich syndrome protein deficiency. <b>2013</b> , 131, 815-24	22
429	Hepatitis B virus X protein protects hepatoma and hepatic cells from complement-dependent cytotoxicity by up-regulation of CD46. <b>2013</b> , 587, 645-51	18

428	The Arg719 residue at the C-terminal end of the stem region in hepatitis C virus JFH-1 E2 glycoprotein promotes viral infection. <b>2013</b> , 172, 1-8	7
427	Down-regulation of Toll-like receptor 7 expression in hepatitis-virus-related human hepatocellular carcinoma. <b>2013</b> , 44, 534-41	20
426	Liver injury and disease pathogenesis in chronic hepatitis C. <b>2013</b> , 369, 263-88	49
425	Effector CD8 T cell trafficking within the liver. <b>2013</b> , 55, 94-9	24
424	Inhibition of hepatitis B virus gene expression and replication by ribonuclease P. <b>2013</b> , 21, 995-1003	22
423	Viral Hepatitis. <b>2013</b> , 290-305	1
422	Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. <b>2013</b> , 19, 859-68	328
421	Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides. <b>2013</b> , 13, 1063-74	2
420	Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development. <b>2013</b> , 31, 138-51	39
419	Encyclopedia of Inflammatory Diseases. <b>2013</b> , 1-14	
418	Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. <b>2013</b> , 9, e1003494	155
417	IL-1 $\beta$ production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. <b>2013</b> , 9, e1003330	302
416	Lymphotoxin signaling is initiated by the viral polymerase in HCV-linked tumorigenesis. <b>2013</b> , 9, e1003234	17
415	TNF $\alpha$ mediated liver destruction by Kupffer cells and Ly6Chi monocytes during Entamoeba histolytica infection. <b>2013</b> , 9, e1003096	65
414	Hepatitis B virus disrupts mitochondrial dynamics: induces fission and mitophagy to attenuate apoptosis. <b>2013</b> , 9, e1003722	182
413	Repeated exposure to trace amounts of woodchuck hepadnavirus induces molecularly evident infection and virus-specific T cell response in the absence of serological infection markers and hepatitis. <b>2013</b> , 87, 1035-48	15
412	Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. <b>2013</b> , 87, 6377-90	32
411	Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle?. <b>2013</b> , 4, 1-25	5

410	Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress. <b>2013</b> , 78, 230-7	6
409	Reduced ADP-ribosylation by PARP1 natural polymorphism V762A and by PARP1 inhibitors enhance Hepatitis B virus replication. <b>2013</b> , 20, 658-65	5
408	Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication. <b>2013</b> , 191, 3264-76	51
407	Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. <b>2013</b> , 89, 294-304	36
406	Analysis and simulation of an Adefovir anti-hepatitis B virus infection therapy immune model with alanine aminotransferase. <b>2013</b> , 7, 205-13	3
405	Inhibition of hepatitis B virus-associated liver cancer by antiplatelet therapy: a revolution in hepatocellular carcinoma prevention?. <b>2013</b> , 57, 848-50	5
404	CD8 and CD4 T cells in west nile virus immunity and pathogenesis. <b>2013</b> , 5, 2573-84	34
403	Computational evolutionary analysis of the overlapped surface (S) and polymerase (P) region in hepatitis B virus indicates the spacer domain in P is crucial for survival. <b>2013</b> , 8, e60098	16
402	Engineered external guide sequences are highly effective in inhibiting gene expression and replication of hepatitis B virus in cultured cells. <b>2013</b> , 8, e65268	6
401	T lymphocytes from chronic HCV-infected patients are primed for activation-induced apoptosis and express unique pro-apoptotic gene signature. <b>2013</b> , 8, e77008	11
400	Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. <b>2014</b> , 1, 183-6	3
399	Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. <b>2014</b> , 5,	1
398	Adaptive immune response during hepatitis C virus infection. <b>2014</b> , 20, 3418-30	40
397	Mechanisms of hepatocarcinogenesis in chronic hepatitis C. <b>2014</b> , 1, 293-307	2
396	Viral Hepatitis?. <b>2014</b> ,	
395	Therapy of Hepatitis B Virus Infections - Potential and Limitations. <b>2014</b> , 57, 131-133	0
394	Non-invasive monitoring of liver fibrosis. <b>2014</b> , 112, 97-106	9
393	Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. <b>2014</b> , 15, 9184-208	55

392	Analysis of T Cell Receptor V $\beta$ Diversity in Peripheral CD4+ and CD8+ T Lymphocytes Obtained From Patients With Chronic Severe Hepatitis B. <b>2014</b> , 14, e15900	9
391	Study of toll-like receptor 7 expression and interferon $\beta$ in Egyptian patients with chronic hepatitis C Infection and Hepatocellular Carcinoma. <b>2014</b> , 15, 387-392	6
390	Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancer. <b>2014</b> , 5, 293	5
389	Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127 <sup>low</sup> T cells in parallel with inhibiting hepatitis B virus DNA. <b>2014</b> , 9, 2024-30	11
388	Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. <b>2014</b> , 39, 1225-34	73
387	Modeling human liver cancer heterogeneity: virally induced transgenic models and mouse genetic models of chronic liver inflammation. <b>2014</b> , 67, Unit 14.31.1-17	4
386	Exportin 4 gene expression and DNA promoter methylation status in chronic hepatitis B virus infection. <b>2014</b> , 21, 241-50	9
385	The allele 4 of neck region liver-lymph node-specific ICAM-3-grabbing integrin variant is associated with spontaneous clearance of hepatitis C virus and decrease of viral loads. <b>2014</b> , 20, O325-32	5
384	Studying the association of microRNA-210 level with chronic hepatitis B progression. <b>2014</b> , 21, 272-80	17
383	Cytokines and HCV-related autoimmune disorders. <b>2014</b> , 60, 311-9	16
382	Depression and neuroticism in patients with chronic hepatitis C: correlation with peripheral blood mononuclear cells activation. <b>2014</b> , 60, 105-11	25
381	Lentiviral backbone-based hepatitis B virus replicon-mediated transfer favours the establishment of persistent hepatitis B virus infection in mice after hydrodynamic injection. <b>2014</b> , 101, 68-74	16
380	Hepatitis B virus X increases immune cell recruitment by induction of chemokine SDF-1. <b>2014</b> , 588, 733-9	10
379	Hepatocellular carcinoma: diagnosis, management, and prognosis. <b>2014</b> , 23, 289-311	49
378	Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice. <b>2014</b> , 49, 11-21	14
377	Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. <b>2014</b> , 111, E1264-73	74
376	Mouse models of hepatitis B and delta virus infection. <b>2014</b> , 410, 39-49	35
375	Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo. <b>2014</b> , 94, 478-90	11

374	Regulation of type I interferon responses. <b>2014</b> , 14, 36-49	1605
373	Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. <b>2014</b> , 58, 3451-60	15
372	Hepatitis B surface antigen inhibits MICA and MICB expression via induction of cellular miRNAs in hepatocellular carcinoma cells. <b>2014</b> , 35, 155-63	28
371	Immune control and failure in HCV infection--tipping the balance. <b>2014</b> , 96, 535-48	33
370	Viral neuropathogenesis. <b>2014</b> , 123, 175-91	3
369	Adaptive response in hepatitis B virus infection. <b>2014</b> , 21, 305-13	31
368	Designing immune therapy for chronic hepatitis B. <b>2014</b> , 4, 241-6	5
367	Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. <b>2014</b> , 4, 248-57	37
366	Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. <b>2014</b> , 111, 6413-8	164
365	The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. <b>2014</b> , 69, 81-7	20
364	Kynurenine production mediated by indoleamine 2,3-dioxygenase aggravates liver injury in HBV-specific CTL-induced fulminant hepatitis. <b>2014</b> , 1842, 1464-71	13
363	Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. <b>2014</b> , 59, 1320-30	38
362	MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. <b>2014</b> , 21, 99-110	31
361	Platelets promote liver immunopathology contributing to hepatitis B virus-mediated hepatocarcinogenesis. <b>2014</b> , 41, 402-5	9
360	Preserved Function of Circulating Invariant Natural Killer T Cells in Patients With Chronic Hepatitis B Virus Infection. <b>2015</b> , 94, e961	6
359	Interplay between hepatitis B virus and innate immune signaling pathways. <b>2015</b> , 448-458	
358	Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana. <b>2015</b> , 147, 1376-1384	8
357	Present and future therapies of hepatitis B: From discovery to cure. <b>2015</b> , 62, 1893-908	211

356	Rethinking the pathogenesis of hepatitis B virus (HBV) infection. <b>2015</b> , 87, 1989-99	19
355	A MAVS/TICAM-1-independent interferon-inducing pathway contributes to regulation of hepatitis B virus replication in the mouse hydrodynamic injection model. <b>2015</b> , 7, 47-58	13
354	Does IL-22 protect against liver fibrosis in hepatitis C virus infection?. <b>2015</b> , 62, 1919	2
353	Immune-mediated Liver Injury in Hepatitis B Virus Infection. <b>2015</b> , 15, 191-8	35
352	RNase P-Mediated Sequence-Specific Cleavage of RNA by Engineered External Guide Sequences. <b>2015</b> , 5, 3029-50	10
351	The chimpanzee model for hepatitis B virus infection. <b>2015</b> , 5,	37
350	The virome in host health and disease. <b>2015</b> , 42, 805-13	114
349	Increased Frequencies of Circulating IFN- $\beta$ -Producing V $\alpha$ (+) and V $\beta$ (+) T Cells in Patients with Asymptomatic Persistent Hepatitis B Virus Infection. <b>2015</b> , 28, 201-8	9
348	Soluble ST2 plasma concentrations predict mortality in HBV-related acute-on-chronic liver failure. <b>2015</b> , 2015, 535938	16
347	On the apparent rarity of epithelial cancers in captive chimpanzees. <b>2015</b> , 370,	22
346	Molecular profile of the T cell receptor beta variable in peripheral blood lymphocytes from chronic asymptomatic HBV carriers. <b>2015</b> , 73, 1-9	7
345	Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage. <b>2015</b> , 43, 974-86	43
344	HBV and the immune response. <b>2015</b> , 35 Suppl 1, 121-8	114
343	Chronic hepatitis B: role of anti-platelet therapy in inflammation control. <b>2015</b> , 12, 264-8	22
342	Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection. <b>2015</b> , 27, 238-43	8
341	Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection. <b>2015</b> , 33, 149-55	16
340	Natural killer cells in hepatitis B virus infection. <b>2015</b> , 19, 417-25	17
339	Host-virus interactions in hepatitis B virus infection. <b>2015</b> , 36, 61-6	97



338	Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. <b>2015</b> , 60, 3513-24	29
337	Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. <b>2015</b> , 21, 969-74	23
336	Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. <b>2015</b> , 63, 1077-85	43
335	Modeling hepatitis B virus infection, immunopathology and therapy in mice. <b>2015</b> , 121, 1-8	24
334	Immune Response in Hepatitis B Virus Infection. <b>2015</b> , 5, a021428	58
333	Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Sera of Patients at Different Phases of Infection. <b>2015</b> , 53, 2203-14	22
332	Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy. <b>2015</b> , 118, 10-9	15
331	Prediction of virological response by pretreatment hepatitis B virus reverse transcriptase quasispecies heterogeneity: the advantage of using next-generation sequencing. <b>2015</b> , 21, 797.e1-8	12
330	Immunosurveillance of the liver by intravascular effector CD8(+) T cells. <b>2015</b> , 161, 486-500	194
329	Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model. <b>2015</b> , 12, 317-25	21
328	Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. <b>2015</b> , 21, 591-600	166
327	Towards personalized medicine in chronic HBV patients?. <b>2015</b> , 35, 1783-5	1
326	Cellular stress responses in hepatitis C virus infection: Mastering a two-edged sword. <b>2015</b> , 209, 100-17	29
325	Prognostic value of the platelet to lymphocyte ratio change in liver cancer. <b>2015</b> , 194, 464-470	29
324	Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1. <b>2015</b> , 39, 711-7	4
323	Repressing PU.1 by miR-29a* in NK cells of HCV patients, diminishes its cytolytic effect on HCV infected cell models. <b>2015</b> , 76, 687-94	7
322	Circulating CD56dim natural killer cells and CD56+ T cells that produce interferon- $\gamma$ interleukin-10 are expanded in asymptomatic, E antigen-negative patients with persistent hepatitis B virus infection. <b>2015</b> , 22, 335-45	16
321	Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro. <b>2015</b> , 15, 255	15

320	Mouse Models of Hepatitis B Virus Pathogenesis. <b>2015</b> , 5,	15
319	The analysis of correlation between IL-12 gene expression and hepatitis B virus in the affected patients. <b>2015</b> , 26, 196-9	3
318	In vivo flow mapping in complex vessel networks by single image correlation. <b>2014</b> , 4, 7341	18
317	Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. <b>2015</b> , 12, 273-82	70
316	Hepatic effector CD8(+) T-cell dynamics. <b>2015</b> , 12, 269-72	10
315	Immunobiology of hepatitis B virus infection. <b>2015</b> , 45, 179-89	36
314	Regulatory CD4+ T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type. <b>2015</b> , 62, 398-404	35
313	The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. <b>2015</b> , 235, 355-67	93
312	Technical standards for hepatitis B virus X protein (HBx) research. <b>2015</b> , 61, 1416-24	53
311	An insight into the molecular characteristics of hepatitis C virus for clinicians. <b>2016</b> , 37, 483-91	3
310	Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo. <b>2016</b> , 7, 68179-68193	24
309	Comparative Analysis of Liver Injury-Associated Cytokines in Acute Hepatitis A and B. <b>2016</b> , 57, 652-7	5
308	Aberrant Immunity: The Consequences of Overreacting or Underperforming. <b>2016</b> , 71-79	
307	Regulatory T Cells in Hepatitis B and C Virus Infections. <b>2016</b> , 16, 330-336	44
306	Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors. <b>2016</b> , 17, 455	21
305	[gMDSCs act as metabolic regulators of hepatitis B virus immunopathology]. <b>2016</b> , 32, 238-41	0
304	Pegylated Interferon $\alpha$ Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion. <b>2016</b> , 11, e0158297	16
303	Production of Autoantibodies in Chronic Hepatitis B Virus Infection Is Associated with the Augmented Function of Blood CXCR5+CD4+ T Cells. <b>2016</b> , 11, e0162241	9

302	Intrahepatic mRNA Expression of FAS, FASL, and FOXP3 Genes Is Associated with the Pathophysiology of Chronic HCV Infection. <b>2016</b> , 11, e0156604	10
301	Altered Immune Profiles of Natural Killer Cells in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. <b>2016</b> , 11, e0160171	10
300	Immune responses and immunopathology in acute and chronic viral hepatitis. <b>2016</b> , 16, 509-23	176
299	NK cells lacking FcRIIb are associated with reduced liver damage in chronic hepatitis C virus infection. <b>2016</b> , 46, 1020-9	13
298	In vivo models of hepatitis B and C virus infection. <b>2016</b> , 590, 1987-99	20
297	Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology. <b>2016</b> , 14, 328	41
296	Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients. <b>2017</b> , 22, 43-51	1
295	KIR : HLA association with clinical manifestations of HBV infection in Madurai, south India. <b>2016</b> , 95, 13-9	8
294	Protective effects of HLA-DPA1/DPB1 variants against Hepatitis B virus infection in an Indonesian population. <b>2016</b> , 41, 177-184	14
293	Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes. <b>2016</b> , 144, 297-305	3
292	Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential. <b>2016</b> , 62 Suppl 4, S281-8	23
291	HBV replication, pathobiology and therapy: Unanswered questions. <b>2016</b> , 64, S1-S3	19
290	Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors. <b>2016</b> , 131, 40-8	16
289	Hepatitis B virus inhibits insulin receptor signaling and impairs liver regeneration via intracellular retention of the insulin receptor. <b>2016</b> , 73, 4121-40	7
288	Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies. <b>2016</b> , 494, 236-47	14
287	Nuclear receptors control pro-viral and antiviral metabolic responses to hepatitis C virus infection. <b>2016</b> , 12, 1037-1045	32
286	Functionally aberrant dendritic cell subsets and expression of DC-SIGN differentiate acute from chronic HBV infection. <b>2016</b> , 10, 916-923	5
285	Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. <b>2016</b> , 29, 1936-1955	153

284	2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. <b>2016</b> , 59, 7311-51	29
283	Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. <b>2016</b> , 23, 874-883	38
282	Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice. <b>2016</b> , 90, 8563-74	14
281	Hepatitis B virus (HBV) X protein-mediated regulation of hepatocyte metabolic pathways affects viral replication. <b>2016</b> , 498, 9-22	26
280	Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology. <b>2016</b> , 20, 629-644	7
279	HBV cure: why, how, when?. <b>2016</b> , 18, 135-43	36
278	Attenuated viral hepatitis in Trem1 <sup>-/-</sup> mice is associated with reduced inflammatory activity of neutrophils. <b>2016</b> , 6, 28556	11
277	Compendium of Inflammatory Diseases. <b>2016</b> , 5-20	1
276	Compendium of Inflammatory Diseases. <b>2016</b> , 117-129	
275	Pleiotropic Roles of Type 1 Interferons in Antiviral Immune Responses. <b>2016</b> , 132, 135-158	17
274	Timing of CD8 T cell effector responses in viral infections. <b>2016</b> , 3, 150661	7
273	T-bet expression in CD8 <sup>+</sup> T cells associated with chronic hepatitis B virus infection. <b>2016</b> , 13, 14	4
272	Type I interferons in viral control and immune regulation. <b>2016</b> , 16, 31-40	116
271	Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. <b>2016</b> , 63, 83-94	30
270	Adaptive immunity in the liver. <b>2016</b> , 13, 354-68	49
269	Host-virus interactions in hepatitis B and hepatitis C infection. <b>2016</b> , 51, 409-20	21
268	Hepatitis B Virus Immunopathogenesis. <b>2016</b> , 79-93	
267	Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. <b>2016</b> , 196, 3079-87	50

266	Effector T cell function rather than survival determines extent and duration of hepatitis in mice. <b>2016</b> , 64, 1327-38	4
265	Novel insights into immunotherapy for hepatitis B patients. <b>2016</b> , 10, 267-76	4
264	Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <b>2016</b> , 150, 684-695.e5	126
263	Experimental Models: Cell Culture and Animal Models. <b>2016</b> , 35-62	
262	M2 Macrophages Play Critical Roles in Progression of Inflammatory Liver Disease in Hepatitis C Virus Transgenic Mice. <b>2016</b> , 90, 300-7	21
261	Effective intrahepatic CD8+ T-cell immune responses are induced by low but not high numbers of antigen-expressing hepatocytes. <b>2016</b> , 13, 805-815	23
260	The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. <b>2016</b> , 23, 576-82	26
259	Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection. <b>2016</b> , 65, 1744-53	27
258	Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. <b>2017</b> , 152, 1297-1309	297
257	Evolution of full-length genomes of HBV quasispecies in sera of patients with a coexistence of HBsAg and anti-HBs antibodies. <b>2017</b> , 7, 661	11
256	Effector CD8 T cell-derived interleukin-10 enhances acute liver immunopathology. <b>2017</b> , 67, 543-548	33
255	Intrahepatic CD206 macrophages contribute to inflammation in advanced viral-related liver disease. <b>2017</b> , 67, 490-500	36
254	Natural killer cells in inflammatory heart disease. <b>2017</b> , 175, 26-33	43
253	Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG. <b>2017</b> , 7, 1957	3
252	Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. <b>2017</b> , 121, 3-8	67
251	Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection. <b>2017</b> , 60, 6461-6479	53
250	Roles for Cell-Cell Adhesion and Contact in Obesity-Induced Hepatic Myeloid Cell Accumulation and Glucose Intolerance. <b>2017</b> , 18, 2766-2779	30
249	Interactions between Th1 cells and Tregs affect regulation of hepatic fibrosis in biliary atresia through the IFN- $\gamma$ /STAT1 pathway. <b>2017</b> , 24, 997-1006	19

248	Clinical Significance of Dynamics of Programmed Death Ligand-1 Expression on Circulating CD14 Monocytes and CD19 B Cells with the Progression of Hepatitis B Virus Infection. <b>2017</b> , 30, 224-231	17
247	Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. <b>2017</b> , 66, 897-909	83
246	An ELISPOT-Based Assay to Measure HBV-Specific CD8 T Cell Responses in Immunocompetent Mice. <b>2017</b> , 1540, 237-247	7
245	Interaction effects among IFN- $\gamma$ 874, IL-2-330, IL-10-1082, IL-10-592 and IL-4-589 polymorphisms on the clinical progression of subjects infected with hepatitis B virus and/or hepatitis C virus: a retrospective nested case-control study. <b>2017</b> , 7, e013279	2
244	The lipid-sensor TREM2 aggravates disease in a model of LCMV-induced hepatitis. <b>2017</b> , 7, 11289	10
243	The promise of 4-1BB (CD137) mediated immunomodulation and immunotherapy for viral diseases. <b>2017</b> , 12, 361-372	1
242	Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: A retrospective analysis of 509 cases. <b>2017</b> , 96, e7438	6
241	Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches. <b>2017</b> , 11, 509-521	12
240	The Principles and Drivers of Cancer. <b>2017</b> , 137-152	
239	Oncogenic Role of Tumor Viruses in Humans. <b>2017</b> , 30, 20-27	40
238	Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses. <b>2017</b> , 89, 388-396	9
237	Determinants of hepatic effector CD8 T cell dynamics. <b>2017</b> , 66, 228-233	17
236	Therapeutic effects of mesenchymal stem cells combined with short hairpin RNA on liver injury induced by hepatitis B virus infection. <b>2018</b> , 17, 1731-1741	2
235	Quantum dot/pMHC multimers vs. phycoerythrin/pMHC tetramers for identification of HLA-A*0201-restricted pHBV core antigen18-27-specific T cells. <b>2017</b> , 16, 8605-8612	
234	IFN- $\gamma$ A Contentious Player in Host-Pathogen Interaction in Tuberculosis. <b>2017</b> , 18,	8
233	Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts. <b>2017</b> , 9,	35
232	Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. <b>2017</b> , 5,	29
231	Q&A: What are pathogens, and what have they done to and for us?. <b>2017</b> , 15, 91	37

230	The neglected avian hepatotropic virus induces acute and chronic hepatitis in ducks: an alternative model for hepatology. <b>2017</b> , 8, 81838-81851	15
229	Halofuginone ameliorates inflammation in severe acute hepatitis B virus (HBV)-infected SD rats through AMPK activation. <b>2017</b> , 11, 2947-2955	3
228	CSFV induced mitochondrial fission and mitophagy to inhibit apoptosis. <b>2017</b> , 8, 39382-39400	34
227	Understanding the Complex Patterns Observed during Hepatitis B Virus Therapy. <b>2017</b> , 9,	4
226	NKT cells in liver diseases. <b>2018</b> , 12, 249-261	19
225	Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics. <b>2018</b> , 68, 473-484	12
224	Hepatitis C Virus Infection and Vaccine Development. <b>2018</b> , 8, 195-204	12
223	An Antigen-Free, Plasmacytoid Dendritic Cell-Targeting Immunotherapy To Bolster Memory CD8 T Cells in Nonhuman Primates. <b>2018</b> , 200, 2067-2075	6
222	Current concepts on immunopathogenesis of hepatitis B virus infection. <b>2018</b> , 245, 29-43	17
221	Innate-like Cytotoxic Function of Bystander-Activated CD8 T Cells Is Associated with Liver Injury in Acute Hepatitis A. <b>2018</b> , 48, 161-173.e5	73
220	Differentially Expressed Intrahepatic Genes Contribute to Control of Hepatitis B Virus Replication in the Inactive Carrier Phase. <b>2018</b> , 217, 1044-1054	18
219	Dysregulated Response of Follicular Helper T Cells to Hepatitis B Surface Antigen Promotes HBV Persistence in Mice and Associates With Outcomes of Patients. <b>2018</b> , 154, 2222-2236	41
218	Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3. <b>2018</b> , 155, 180-193.e6	44
217	Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. <b>2018</b> , 8, 4968	33
216	Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver. <b>2018</b> , 154, 1778-1790	87
215	Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. <b>2018</b> , 437, 13-36	27
214	Recombinant covalently closed circular DNA of hepatitis B virus induces long-term viral persistence with chronic hepatitis in a mouse model. <b>2018</b> , 67, 56-70	30
213	Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels. <b>2018</b> , 48, E133-E145	25

212	Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice. <b>2018</b> , 149, 41-47	24
211	Mechanisms of Hepatitis B Virus Persistence. <b>2018</b> , 26, 33-42	91
210	Mechanisms of Disease. <b>2018</b> , 145-157	
209	Hepatitis viruses. <b>2018</b> , 106-120	
208	Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives. <b>2018</b> , 9, 20891-20907	24
207	Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. <b>2018</b> , 9, 3158	41
206	The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions. <b>2018</b> , 19,	30
205	Identification of serum Ectenin as a biomarker in patients with HBV-related liver diseases. <b>2018</b> , 16, 265	9
204	Cell-Mediated Immune Responses and Immunopathogenesis of Human Tick-Borne Encephalitis Virus-Infection. <b>2018</b> , 9, 2174	13
203	Host phosphatidic acid phosphatase lipin1 is rate limiting for functional hepatitis C virus replicase complex formation. <b>2018</b> , 14, e1007284	10
202	The role of the NLRP3 inflammasome and the activation of IL-1 $\beta$ in the pathogenesis of chronic viral hepatic inflammation. <b>2018</b> , 110, 389-396	22
201	Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications. <b>2018</b> , 37, 455-467	29
200	Liver HLA-E Expression Is Associated with Severity of Liver Disease in Chronic Hepatitis C. <b>2018</b> , 2018, 2563563	8
199	The dynamics of integration, viral suppression and cell-cell transmission in the development of occult Hepatitis B virus infection. <b>2018</b> , 455, 269-280	7
198	Analysis of risk factors associated with hepatocellular carcinoma in black South Africans: 2000-2012. <b>2018</b> , 13, e0196057	18
197	Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B. <b>2018</b> , 6,	45
196	Hepatitis B Virus Infection Predicts Better Survival In Patients With Colorectal Liver-only Metastases Undergoing Liver Resection. <b>2018</b> , 9, 1560-1567	6
195	Pre-Activation of Toll-Like Receptor 2 Enhances CD8 T-Cell Responses and Accelerates Hepatitis B Virus Clearance in the Mouse Models. <b>2018</b> , 9, 1495	13



194	Sustained IFN-I Expression during Established Persistent Viral Infection: A "Bad Seed" for Protective Immunity. <b>2017</b> , 10,	23
193	Outcome of Antiviral Immunity in the Liver Is Shaped by the Level of Antigen Expressed in Infected Hepatocytes. <b>2018</b> , 68, 2089-2105	5
192	Threshold behavior in a stochastic HTLV-I infection model with CTL immune response and regime switching. <b>2018</b> , 41, 6866-6882	10
191	Intracellular interleukin-32 mediates antiviral activity of cytokines against hepatitis B virus. <b>2018</b> , 9, 3284	21
190	Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. <b>2018</b> , 285, 38-54	22
189	Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection. <b>2018</b> , 10, 941-951	30
188	Hepatitis B and C. <b>2018</b> , 22, 703-722	27
187	Hepatitis B. <b>2018</b> , 395-420	
186	Hepatitis C Vaccines. <b>2018</b> , 375-385.e5	
185	Pharmacological effects of ginseng on infectious diseases. <b>2019</b> , 27, 871-883	17
184	Infection phase is a predictor of pruritus in patients with hepatitis B virus infection. <b>2019</b> , 11, 63-69	0
183	Identification of key genes, pathways and potential therapeutic agents for liver fibrosis using an integrated bioinformatics analysis. <b>2019</b> , 7, e6645	12
182	Is PD-1 blockade a potential therapy for HBV?. <b>2019</b> , 1, 142-144	8
181	Dynamics and genomic landscape of CD8 T cells undergoing hepatic priming. <b>2019</b> , 574, 200-205	80
180	Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. <b>2019</b> , 16, 662-675	54
179	Inherited IL-18BP deficiency in human fulminant viral hepatitis. <b>2019</b> , 216, 1777-1790	42
178	Acetaldehyde suppresses the display of HBV-MHC class I complexes on HBV-expressing hepatocytes. <b>2019</b> , 317, G127-G140	15
177	Immunological Features of AECHB. <b>2019</b> , 223-314	

176	What Have We Learned from Studies of IFN- $\lambda$ Variants and Hepatitis C Virus Infection?. <b>2019</b> , 39, 618-626	2
175	HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. <b>2019</b> , 20,	27
174	Noninvasive Biomarkers for the Diagnosis of Liver Fibrosis and Cirrhosis. <b>2019</b> ,	
173	Pregenomic RNA: How to assist the management of chronic hepatitis B?. <b>2019</b> , 29, e2051	8
172	Distinct phenotype and function of circulating V $\alpha$ 1+ and V $\alpha$ 2+ T $\beta$ 1-cells in acute and chronic hepatitis B. <b>2019</b> , 15, e1007715	17
171	A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study. <b>2019</b> , 1120, 1-7	17
170	Chronic hepatitis B: The interplay between intrahepatic lymphocyte population and viral antigens in relation to liver damage. <b>2019</b> , 26, 727-737	3
169	HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. <b>2019</b> , 11,	7
168	Hepatitis Viruses. <b>2019</b> ,	
167	Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. <b>2019</b> , 65, 37-55	238
166	Short-term use of MyD88 inhibitor TJ-M2010-5 prevents d-galactosamine/lipopolysaccharide-induced acute liver injury in mice. <b>2019</b> , 67, 356-365	10
165	Immunological cure of HBV infection. <b>2019</b> , 13, 113-124	20
164	A high seroprevalence of human herpesvirus type 8 already present in patients with chronic hepatitis before the development of cirrhosis. <b>2019</b> , 51, 86-90	4
163	Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. <b>2019</b> , 156, 400-417	21
162	T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders. <b>2019</b> , 342, 175-263	3
161	Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice. <b>2019</b> , 10, 221	37
160	Viral Hepatitis. <b>2020</b> , 308-324	0
159	An HBV-encoded miRNA activates innate immunity to restrict HBV replication. <b>2020</b> , 12, 263-276	22

158	Genetic association of polymorphisms at the intergenic region between PRDM1 and ATG5 with hepatitis B virus infection in Han Chinese patients. <b>2020</b> , 92, 1198-1205	7
157	Organ Damage and Failure. <b>2020</b> , 289-307	
156	Platelet activation during chronic hepatitis B infection exacerbates liver inflammation and promotes fibrosis. <b>2019</b> , 92, 3319	1
155	ROS/NF-B Signaling Pathway-Mediated Transcriptional Activation of TRIM37 Promotes HBV-Associated Hepatic Fibrosis. <b>2020</b> , 22, 114-123	11
154	Liver Cirrhosis in Chronic Hepatitis B Patients Is Associated with Genetic Variations in DNA Repair Pathway Genes. <b>2020</b> , 12,	3
153	Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. <b>2020</b> , 217,	12
152	Immune surveillance of the liver by T cells. <b>2020</b> , 5,	20
151	Key Players of Hepatic Fibrosis. <b>2020</b> , 40, 472-489	13
150	Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection. <b>2020</b> , 8,	10
149	Acute-on-Chronic Liver Failure From Chronic-Hepatitis-B, Who Is the Behind Scenes. <b>2020</b> , 11, 583423	7
148	A High Preoperative Platelet-Lymphocyte Ratio Is a Negative Predictor of Survival After Liver Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma:. <b>2020</b> , 10, 576205	4
147	Diverse Virus and Host-Dependent Mechanisms Influence the Systemic and Intrahepatic Immune Responses in the Woodchuck Model of Hepatitis B. <b>2020</b> , 11, 853	5
146	Role of non-Genetic Risk Factors in Exacerbating Alcohol-related organ damage. <b>2020</b> , 87, 63-72	0
145	Hepatitis B Virus Reactivation Potentiated by Biologics. <b>2020</b> , 34, 341-358	10
144	Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?. <b>2020</b> , 24, 317-333	14
143	Johannesburg Cancer Study (JCS): contribution to knowledge and opportunities arising from 20 years of data collection in an African setting. <b>2020</b> , 65, 101701	4
142	Transcriptional insights into the CD8 T cell response in mono-HIV and HCV infection. <b>2020</b> , 18, 96	1
141	Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. <b>2020</b> , 15, 406-416	71

140	Osteopetrosis-Associated Transmembrane Protein 1 Recruits RNA Exosome To Restrict Hepatitis B Virus Replication. <b>2020</b> , 94,	5
139	Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. <b>2021</b> , 74, 794-800	11
138	Metabolic regulation of the HBV-specific T cell function. <b>2021</b> , 185, 104989	1
137	Mechanisms of Hepatitis B Virus-Induced Hepatocarcinogenesis. <b>2021</b> , 217, 47-70	3
136	HBsAg-specific CD8 T cells as an indispensable trigger to induce murine hepatocellular carcinoma. <b>2021</b> , 18, 128-137	6
135	A systematic study of Tupaia as a model for human acute hepatitis B infection. <b>2021</b> , 83, 1004-1011	1
134	The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy. <b>2021</b> , 2021, 2178143	0
133	Early events in hepatitis B infection: the role of inoculum dose. <b>2021</b> , 288, 20202715	3
132	The Impact of Hepatitis C Virus Genotypes on Oxidative Stress Markers and Catalase Activity. <b>2021</b> , 2021, 6676057	1
131	Hepatitis B Reactivation: A Review of Clinical Guidelines. <b>2021</b> , 55, 393-399	1
130	HLA-E gene polymorphisms in chronic hepatitis C: Impact on HLA-E liver expression and disease severity. <b>2021</b> , 82, 177-185	1
129	Activation and Inhibition of the NLRP3 Inflammasome by RNA Viruses. <b>2021</b> , 14, 1145-1163	11
128	Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review. <b>2021</b> , 150, 112087	10
127	Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg 2021, 9, 633792	0
126	Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression. <b>2021</b> , 11, 7772	1
125	Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver. <b>2021</b> , 6,	4
124	Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. <b>2021</b> , 27, 2312-2324	2
123	Immunobiology and pathogenesis of hepatitis B virus infection. <b>2021</b> ,	41

122	Serum HBV pregenomic RNA exhibited opposite associations with NKdim and NKbright cell immunity in treatment-naïve chronic hepatitis B patients. <b>2021</b> , 41,	0
121	Engineered chimeric T cell receptor fusion construct (TRuC)-expressing T cells prevent translational shutdown in SARS-CoV-2-infected cells.	
120	lncRNA-HEIM Facilitated Liver Fibrosis by Up-Regulating TGF- Expression in Long-Term Outcome of Chronic Hepatitis B. <b>2021</b> , 12, 666370	1
119	T cells protect against hepatitis A virus infection and limit infection-induced liver injury. <b>2021</b> , 75, 1323-1334	4
118	Threshold Dynamics of a Non-Linear Stochastic Viral Model with Time Delay and CTL Responsiveness. <b>2021</b> , 11,	2
117	Hepatocyte-derived L-carnitine restricts hepatitis B surface antigen loss through an immunosuppressive effect on germinal center-related immune cells. <b>2021</b> ,	
116	Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI). <b>2021</b> , 23, 99	
115	Research Progress on the Natural Product Aloperine and Its Derivatives. <b>2021</b> ,	1
114	Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. <b>2021</b> , 9,	2
113	Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical.	
112	Prospects for the Global Elimination of Hepatitis B. <b>2021</b> , 8, 437-458	0
111	Viral and Host Factors Affecting Disease Progression of Hepatitis B Virus Infection. <b>2021</b> , 205-230	
110	A Cell Culture Model for Persistent HCV Infection. <b>2019</b> , 1911, 157-168	1
109	The Liver as an Immune-Privileged Site. <b>2012</b> , 93-106	4
108	The Hepatobiliary System. <b>2009</b> , 263-289	1
107	Infectious Diseases. <b>2010</b> , 331-398	11
106	Diagnostic accuracy of hepatocyte growth factor, Fas/CD95 and Endostatin for non-invasive assessment of hepatic fibrosis in biopsy-proven hepatitis C virus patients. <b>2020</b> , 85, 104526	1
105	Inhibition of hepatitis B virus replication by activation of the cGAS-STING pathway. <b>2016</b> , 97, 3368-3378	28

104	Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. <b>2011</b> , 121, 37-56	260
103	Associations between pre-S deletion mutation of hepatitis B virus and risk of hepatocellular carcinoma in the Asian population: a meta-analysis. <b>2015</b> , 21, 1072-7	13
102	Interleukin-6 induces Gr-1+CD11b+ myeloid cells to suppress CD8+ T cell-mediated liver injury in mice. <b>2011</b> , 6, e17631	42
101	Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. <b>2011</b> , 6, e19799	13
100	Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. <b>2012</b> , 7, e50035	33
99	Identification and characterization of multiple TRIM proteins that inhibit hepatitis B virus transcription. <b>2013</b> , 8, e70001	34
98	Bone marrow transplantation concurrently reconstitutes donor liver and immune system across host species barrier in mice. <b>2014</b> , 9, e106791	1
97	A novel mouse model for stable engraftment of a human immune system and human hepatocytes. <b>2015</b> , 10, e0119820	59
96	Novel mechanism of arenavirus-induced liver pathology. <b>2015</b> , 10, e0122839	13
95	On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. <b>2017</b> , 12, e0179096	37
94	The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study. <b>2017</b> , 12, e0181004	7
93	Hepatitis C Virus Stimulates Murine CD8 $\alpha$ -like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. <b>2016</b> , 12, e1005736	4
92	Activation of intrahepatic CD4+CXCR5+ T and CD19+ B cells is associated with viral clearance in a mouse model of acute hepatitis B virus infection. <b>2016</b> , 7, 50952-50962	4
91	Hepatic NK cell-mediated hypersensitivity to ConA-induced liver injury in mouse liver expressing hepatitis C virus polyprotein. <b>2017</b> , 8, 52178-52192	6
90	Hepatic stroma-educated regulatory DCs suppress CD8 T cell proliferation in mice. <b>2017</b> , 8, 93414-93425	1
89	ADCC-Mediated CD56 NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection. <b>2018</b> , 3, 2-18	16
88	Immune therapy for hepatitis B. <b>2016</b> , 4, 335	3
87	Innate and Adaptive Immune Responses in Chronic HCV Infection. <b>2017</b> , 18, 826-843	31

86	Molecular mechanisms of hepatic fibrosis in chronic liver diseases. <b>2020</b> , 32,	9
85	Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load. <b>2009</b> , 15, 3382-93	6
84	Impact of alcohol on hepatitis C virus replication and interferon signaling. <b>2010</b> , 16, 1337-43	32
83	Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection. <b>2014</b> , 20, 6707-15	13
82	Progress in the development of vaccines for hepatitis C virus infection. <b>2015</b> , 21, 11984-2002	27
81	Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. <b>2016</b> , 22, 6469-83	31
80	Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. <b>2018</b> , 24, 3488-3499	21
79	Immune suppression in chronic hepatitis B infection associated liver disease: A review. <b>2019</b> , 25, 3527-3537	32
78	HBV core region variability: effect of antiviral treatments on main epitopic regions. <b>2011</b> , 16, 37-49	11
77	Comparison of Immunogenicity in Balb/C Mice of Commercially Available Recombinant Hepatitis B Vaccines in Iran. <b>2008</b> , 8, 415-419	1
76	How virus persistence can initiate the tumorigenesis process. <b>2013</b> , 2, 102-9	7
75	The First Report of Hepatitis B Virus Prevalence in Skardu, Gilgit Baltistan: A Neglected Area of Pakistan. <b>2018</b> , 11,	1
74	Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus. <b>2021</b> , 1	2
73	A Case of Hepatitis B Virus Reactivation Triggered by Acute Epstein-Barr Virus Infection. <b>2021</b> , 13, e18676	
72	Hepatocellular Carcinoma Associated with Hepatitis B Virus. <b>2009</b> , 235-257	
71	Viral Hepatitis B. <b>2011</b> , 553-567	
70	Hepatitis B and D Viruses. <b>2011</b> , 1659-1676	
69	Experimental Models of Mixed Cryoglobulinemia. <b>2012</b> , 145-153	

68	Immune Pathogenesis of Viral Hepatitis B and C. <b>2012</b> , 111-128	1
67	Human Diseases Prosecution Among Viral Infection and Food Toxins: A Review. <b>2013</b> , 9, 390-404	0
66	Hepatitis Viruses: Hepatitis B and Hepatitis D. <b>2014</b> , 747-764	1
65	Hepatitis B Virus: Pathogenesis and Host Immune Response. <b>2014</b> , 113-132	
64	Perihepatic nodes detected by point-of-care ultrasound in acute hepatitis and acute-on-chronic liver disease. <b>2015</b> , 21, 12620-7	1
63	Protective and Pathogenic T Cell Responses to Virus Infections. <b>2016</b> , 318-323	
62	Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses. <b>2016</b> , 22, 5623-6	
61	Immunopathology of the Hepatobiliary System. <b>2017</b> , 329-417	
60	HBV and the importance of TLR9 on B cell responses. <b>2017</b> , 1, 124-137	0
59	Viral Factors Affecting Disease Progression. <b>2018</b> , 119-133	0
58	Molecular Pathology Introduction and Research Review. <b>2018</b> , 1-15	
57	Hepatitis D. <b>2019</b> , 169-182	
56	Occurrence of Interleukin-2 (330 G/T) Promoter Polymorphism in ARV associated hepatotoxicity. <b>2019</b> , 19, 206-215	
55	Hepatitis B virus reactivation: overview and management.	0
54	Akute und chronische Hepatitis. <b>2020</b> , 187-254	
53	Hepatitis C. <b>2020</b> , 273-286	
52	Gordon Wilson Lecture: Infectious Disease Causes of Cancer: Opportunities for Prevention and Treatment. <b>2015</b> , 126, 117-32	8
51	Immunoregulation of hepatitis B virus infection--rationale and clinical application. <b>2012</b> , 74, 217-32	5



50	Cyclin D1 in the Liver: Role of Noncanonical Signaling in Liver Steatosis and Hormone Regulation. <b>2017</b> , 17, 56-65	7
49	Genetic Polymorphisms of Fas/FasL Promoter Associated with Hepatitis C cirrhosis and HCC. <b>2017</b> , 18, 2683-2688	1
48	New insights into Nod-like receptors (NLRs) in liver diseases. <b>2018</b> , 10, 1-16	8
47	Hepatitis B Virus Reactivation in the Setting of Immunosuppressive Drug Therapy. <b>2019</b> , 15, 585-592	
46	Modulation of Production of Th1/Th2 Cytokines in Peripheral Blood Mononuclear Cells and Neutrophils by Hepatitis C Virus Infection in Chronically Infected Patients. <b>2021</b> , 10,	0
45	[Hepatitis B and C: mechanisms of virus-induced liver pathogenesis and tumorigenesis].. <b>2022</b> , 1	0
44	Hepatitis B Virus Reactivation Associated With Therapeutic Interventions.. <b>2021</b> , 8, 770124	1
43	Microbiota-Mediated Immunity Abnormalities Facilitate Hepatitis B Virus Co-Infection in People Living With HIV: A Review.. <b>2021</b> , 12, 755890	2
42	Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B. <b>2022</b> , 2, 1-14	
41	Induction of thymic atrophy and loss of thymic output by type-I interferons during chronic viral infection.. <b>2021</b> , 567, 77-86	
40	Interferon- $\beta$ acts directly on T $\beta$ cells to prolong allograft survival by enhancing regulatory T cell induction through Foxp3 acetylation.. <b>2022</b> ,	1
39	Advances in new antivirals for chronic hepatitis B.. <b>2022</b> , 135,	0
38	Hepatitis Viruses: Hepatitis B and Hepatitis D. <b>2022</b> , 1-38	
37	Research Progress of HLA and Hepatitis B Virus Infection. <b>2022</b> , 12, 1036-1039	
36	Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.. <b>2022</b> ,	1
35	Group 1 ILCs regulate T cell-mediated liver immunopathology by controlling local IL-2 availability.. <b>2022</b> , 7, eabi6112	0
34	HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection.. <b>2022</b> , 13, 853346	0
33	High-fat-induced nonalcoholic fatty liver potentiates vulnerability to and the severity of viral hepatitis in a C3H/HeN mouse model.. <b>2021</b> ,	

- 32 data\_sheet\_1.DOCX. **2018**,
- 31 Data\_Sheet\_1.docx. **2020**,
- 30 Image\_1.TIF. **2020**,
- 29 Image\_2.TIF. **2020**,
- 28 Image\_3.TIF. **2020**,
- 27 Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. **2022**, 11, 567 2
- 26 Role of Innate Immune Regulatory Genes, and in Chronic Hepatitis B Infection.. **2022**, 35, 338-344
- 25 Consistent discrete global dynamics of a general initial boundary value problem for hepatitis B virus infection with capsids and adaptive immunity. **2022**, 28, 777-852
- 24 Intravital Imaging of Inflammatory Response in Liver Disease. 10, 0
- 23 HBV cccDNA-A Culprit and Stumbling Block for the Hepatitis B Virus Infection: Its Presence in Hepatocytes Perplexed the Possible Mission for a Functional Cure. **2022**, 7, 24066-24081 0
- 22 The infectivity and pathogenicity of Hepatitis A virus live-attenuated vaccine strain H2 in type I interferon receptor-deficient mice. **2022**, 0
- 21 Predicting Hepatitis B e Antigen seroconversion after pregnancy [The SydPregScore ..
- 20 Post-liver transplant HBV infection (Review). **2022**, 24, 31-38
- 19 Mesenchymal stem cells-based therapy in liver diseases. **2022**, 3,
- 18 APOBEC3B: Future direction of liver cancer research. 12, 0
- 17 The Role of NLRP3 Inflammasome Activation in Podocyte Pyroptosis in Hepatitis B Virus Associated-Glomerulonephritis. **2022**, 12, 7012-7025 0
- 16 Prevention of Hepatitis B Reactivation in Patients Receiving Immunosuppressive Therapy: a Case Series and Appraisal of Society Guidelines. 0
- 15 Advances in Immunotherapy for Hepatitis B. **2022**, 11, 1116 0

14	Current Best Practice in Hepatitis B Management and Understanding Long-Term Prospects for Cure. <b>2022</b> ,	0
13	Fulminant Viral Hepatitis in Two Siblings with Inherited IL-10RB Deficiency.	0
12	SaClassification and survival prediction in early-stage cirrhosis by gene expression profiling.	0
11	Studying Hepatitis Virus-Host Interactions in Patient Liver Biopsies. <b>2022</b> , 14, 2490	1
10	Acute Hepatitis. <b>2023</b> , 419-423.e2	0
9	Identification of antibodies cross-reactive with woodchuck immune cells and activation of virus-specific and global cytotoxic T cell responses by anti-PD-1 and anti-PD-L1 in experimental chronic hepatitis B and persistent occult hepadnaviral infection. 13,	0
8	Early Clinical Efficacy of Pegylated Interferon Treatment in Patients with Different Phases of Chronic HBV Infection:A Real-world Analysis.	0
7	Liver immunity, autoimmunity, and inborn errors of immunity. 15, 52-67	0
6	Ligand-free high loading capacity ursolic acid self-carried nanovesicles enable hepatocyte targeting via absorbing apolipoproteins. <b>2023</b> , 638, 122931	0
5	Abnormally primed CD8 T cells: The Achilles heel of CHB. 14,	0
4	A RNase P Ribozyme Inhibits Gene Expression and Replication of Hepatitis B Virus in Cultured Cells. <b>2023</b> , 11, 654	0
3	Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis. 14,	0
2	Development and investigation of metabolism-associated risk assessment models for patients with viral hepatitis. 13,	0
1	Forthcoming Developments in Models to Study the Hepatitis B Virus Replication Cycle, Pathogenesis, and Pharmacological Advancements.	0